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Abstract
The term ‘ﬁeld cancerization’ is used to describe an epithelial surface that has a propensity to develop cancerous
lesions, and in the case of the aerodigestive tract this is often as a result of chronic exposure to carcinogens
in cigarette smoke [1,2]. The clinical endpoint is the development of multiple tumours, either simultaneously
or sequentially in the same epithelial surface. The mechanisms underlying this process remain unclear; one
possible explanation is that the epithelium is colonized by a clonal population of cells that are at increased
risk of progression to cancer. We now address this possibility in a short case series, using individual genomic
events as molecular biomarkers of clonality. In squamous lung cancer the most common genomic aberration is
3q ampliﬁcation. We use a digital PCR technique to assess the clonal relationships between multiple biopsies
in a longitudinal bronchoscopic study, using amplicon boundaries as markers of clonality. We demonstrate that
clonality can readily be deﬁned by these analyses and conﬁrm that ﬁeld cancerization occurs at a pre-invasive
stage and that pre-invasive lesions and subsequent cancers are clonally related. We show that while the amplicon
boundaries can be shared between different biopsies, the degree of 3q ampliﬁcation and the internal structure
of the 3q amplicon varies from lesion to lesion. Finally, in this small cohort, the degree of 3q ampliﬁcation
corresponds to clinical progression.
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Introduction
The term ‘ﬁeld cancerization’ was ﬁrst coined many
years ago [1] and the potential underlying biological
processes have been studied and discussed at length,
particularly in cancers of the aerodigestive tract [2,3].
Three possible mechanisms for ﬁeld cancerization have
been mooted in lung cancer [4]. First, an epithelial
surface exposed to repeated insult, such as cigarette
carcinogens, could develop multiple separate dysplastic
foci that do not originate from a single clone but share
similar genetic aberrations as a result of the common
carcinogenic insult. In time, one or more of these
foci may progress to cancer. A second mechanism
would be that a mutant clone expands and migrates
to colonize the epithelial surface, without breaching
the basement membrane, and that molecular divergence
results in subclonal populations that may or may
not progress. In the third explanation an established
cancer spreads to form multifocal clonal tumours.
It is also entirely possible that these mechanisms
coexist.
In the past shared mutations (particularly of TP53)
or patterns of loss of heterozygosity (LOH) have
been the main biomarkers used to infer the presence
or absence of a clonal relationship between sepa-
rate biopsies from a single individual in lung cancer
and pre-invasive bronchial dysplasia [5–9]. It could
be argued that deﬁning a speciﬁc shared mutation
in TP53, a gene with multiple different mutational
hotspots, with or without supportive LOH studies, is
more suggestive of clonality than LOH patterns alone
[10]. In a seminal case report, it was demonstrated
that multiple, anatomically distinct biopsies from an
individual with widespread mild dysplasia had a com-
mon mutation in TP53, indicating epithelial coloniza-
tion at a pre-invasive stage [11]. More recently a
report on 70 multifocal lung cancers from 30 individ-
uals suggested, on the basis of both LOH and TP53
mutational analysis, that in 77% of individuals the
lesions were clonally related, and concluded that the
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mechanism underlying their monoclonal origin was
local and intrapulmonary metastasis from established
cancers [12]. An accompanying editorial summarized
the current knowledge in this ﬁeld but noted that it
was not possible to exclude pre-invasive clonal migra-
tion as an alternative mechanism [4]. Therefore, our
understanding of the processes underlying bronchial
ﬁeld cancerization remains incomplete.
We have recently demonstrated that a digital PCR
technique, microdissection molecular copy-number
counting (µMCC), can provide detailed high-resolution
information on structural genomic events in archived
pre-invasive bronchial biopsies, in which the amount of
available tissue for analysis is signiﬁcantly limited and
the DNA is of poor quality [13]. We used this approach
to show that 3q ampliﬁcation is consistently observed
in high-grade, but not low-grade, bronchial dysplastic
lesions, and that the likely focus of this ampliﬁcation
is SOX2 [14], consistent with recent results from other
groups [15,16].
We now apply the µMCC technique to the ques-
tion of establishing whether clonal relationships exist
between lesions from separate parts of the bronchial
tree. We use samples from a longitudinal broncho-
scopic study, the Early Lung Cancer Project at UCLH,
many of which have already been used in research
studies [6,7,14,17]. This study was prompted by an
observation that at very low resolution (2 Mb) a high-
grade lesion and a subsequent cancer appeared to share
amplicon boundaries [14]. We have now used ultra-
high-resolution analysis of shared amplicon boundaries
to deﬁne clonal relationships between microdissected
biopsies taken from anatomically distinct parts of the
bronchial tree in the same individuals. This type of
approach has been used at lower resolution to infer
clonality in cancer [18–22]. In this study we apply it
to pre-invasive lesions for the ﬁrst time.
Materials and methods
Patients and samples
The patients were enrolled in the University College
London Hospital Early Lung Cancer Project (ELCP).
This is a longitudinal bronchoscopic surveillance study
that has been described previously [17]. At the time
of enrolment none of the patients had an active
diagnosis of lung cancer, although they may have had
a prior history of lung cancer. Local Regional Ethical
Committee approval was obtained (01/0148). Further
details of the methodology and protocol for histological
diagnosis have been published [14,17]. Clinical details
of the three patients who are the subject of this
publication have been published previously [7,14].
Microdissection molecular copy-number counting
(µMCC)
This protocol has been described recently [13,23]. To
summarize, dysplastic epithelium was microdissected
from haemotoxylin and eosin (H&E)-stained sections
of formalin-ﬁxed parafﬁn-embedded blocks, using the
Arcturus Pixcell II system (Applied Biosystems, USA)
in order to minimize any contamination from stroma or
normal epithelium. Genomic DNA was extracted from
the microdissected cells using the Qiagen DNeasy kit
(Qiagen, UK), as previously described [13]. Limiting
dilution single-molecule PCR was then performed on
the template DNA in a two-stage hemi-nested PCR.
The ﬁrst stage is a multiplex reaction, allowing the
same template to be simultaneously interrogated for
multiple loci; the second a singleplex reaction, assay-
ing each locus individually. For each amplicon bound-
ary, multiple iterative experiments were performed,
as previously described [13], to reﬁne boundaries to
high resolution. Primers were designed as previously
described [13] and all primer sequences are available
on request. All genomic loci were from the Ensembl
database (www.ensembl.org), NCBI Build 36.
TP53 sequencing
In the case of one patient, DNA was extracted from
biopsies taken at the same bronchoscopy and from
the same anatomical location as the lesions used for
µMCC. 20 ng DNA was used in a nested PCR protocol
for each of exons 5–8 of TP53. The primer sequences
used are available on request.
Results
Case histories
These have been published previously [7,14] and are
therefore summarized brieﬂy here.
Case 1 (patient 002)
This patient presented with multifocal left-sided
high-grade bronchial dysplasia. She entered the surveil-
lance programme and eventually proceeded to a left
lower lobectomy for a radiologically occult stage
1A squamous lung cancer. Twenty-one (HG14) and
13 months (HG1) prior to the left lower lobectomy,
bronchoscopies were performed in which biopsies were
taken from the left upper and lower lobes.
Previously, the proximal 3q amplicon junction was
resolved in the stage 1A cancer to an approximately
7 kb interval, spanning a full-length L1 repeat ele-
ment [13]. After repeated rounds of µMCC, it was
demonstrated that the boundary lay on either side of
a full-length L1 repeat element. We took a similar
approach to deﬁne the distal boundary of this amplicon
and resolved this to an interval of 1.9 kb. The primers
used to interrogate the amplicon boundaries in the can-
cer were then applied to prior biopsies from the same
individual (Figure 1). It was readily demonstrated that
both the proximal and distal amplicon boundaries were
shared between all three biopsies (Figure 1; see also
Supporting information, Figure S1). Moreover, there
Copyright  2011 Pathological Society of Great Britain and Ireland. J Pathol 2011; 224: 153–159
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.comClonality and bronchial dysplasia 155
Figure 1. Patient 002—clinical progression is associated with progressive and clonal changes in amplicon structure. (a) Patient 002 had
multiple surveillance bronchoscopies over a 21 month period. Comparative µMCC analysis of three lesions was performed, one (HG 14)
taken at a bronchoscopy at month 0, another at month 8 (HG1) and the ﬁnal biopsy (CA1) at month 21. The upper lobe lesion (green)
regressed. The lower lobe lesion (blue) progressed to cancer after 13 months (black). Some of the data from HG1 and CA1 have been
presented previously [14]#. (b) The amplicon differed in structure between the three lesions. µMCC results from the three lesions were
compared. There was more pronounced 3q ampliﬁcation in HG1 that progressed compared to HG14 that did not, and a further increase in
3q ampliﬁcation in the subsequent cancer CA1. The µMCC proﬁles suggested that all three lesions shared a centromeric amplicon boundary.
(c) Ultra-high resolution µMCC of the transition region was performed. The amplicon boundary was resolved to within a full-length L1
repeat element (locus 168, 475, 750–168, 481, 748) by the use of amplimers that straddled the start and end of the L1 (c, insert). This
change in copy number was not present in DNA extracted from lung tissue adjacent to the resected cancer (red) (c). The results were
normalized to the mean of the reference loci results for (a) and (b), and to the average of the pre-amplicon markers in (c).
was a marked difference in the amplitude of 3q gain
in the separate biopsies. The left lower lobe lesion,
which progressed to cancer, had greater 3q ampliﬁca-
tion than the upper lobe lesion that did not progress.
As previously demonstrated for SOX2 [14], there was
an incremental gain in 3q ampliﬁcation between the
high-grade pre-invasive lesion and the cancer, with a
preserved amplicon junction. The observation that the
cancer (CA1) and the preceding left lower lobe high-
grade lesion (HG1) share common amplicon bound-
aries conﬁrms the clonal evolution of a pre-invasive
lesion to an invasive cancer in this patient.
Case 2 (patient 017)
This patient underwent a left upper lobectomy in
February 2003 for squamous lung cancer (SQC). A
# Please note that versions of Figures 1a, 2a and 3a that illustrate the
patients’ clinical history and some of the associated µMCC data have
been published previously [7,14]. Reprinted with permission of the
American Thoracic Society. Copyright  American Thoracic Society.
subsequent biopsy, taken in 2003 (HG11), and a
later resection specimen after completion pneumonec-
tomy showed high-grade pre-invasive disease but no
evidence of invasive disease. At the initial post-
pneuonectomy bronchoscopy there was no histological
evidence of high-grade dysplasia, but at subsequent
bronchoscopies HGD was detected in the lower trachea
(HG5) and a later biopsy from the pneumonectomy
stump showed invasive cancer (CA2).
Low-resolution µMCC of HG5 performed previously
revealed a focal amplicon distally on 3q [14]. The
boundaries of this amplicon were now deﬁned at high
resolution and a similar analysis was performed on
all three specimens. The three epithelial biopsies had
a common telomeric amplicon boundary, indicating a
clonal origin (Figure 2). The later biopsies had both
developed a focal precentromeric amplicon on 3p.
Interestingly, although the 3q amplicon from both of
the later biopsies shared a centromeric boundary, again
within a full-length L1 element, the earlier lesion had
an adjacent but not identical boundary. In this patient
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Figure 2. Patient 017—clinical progression is associated with progressive and clonal changes in amplicon structure (a) Comparison of
sequential bronchial biopsies from patient 017, who underwent a left upper lobectomy (dashed bar) for squamous cell carcinoma prior to
entering the study. He was subsequently found to have high-grade dysplasia in the resection margin and had a number of surveillance
bronchoscopies. Although there was no biopsy-proven evidence of invasion, there was a clinical suspicion of cancer, so he proceeded to a
pneumonectomy (solid bar) at month 15. The pneumonectomy specimen conﬁrmed high-grade pre-invasive disease with no focal invasion.
Subsequent biopsies at 17 and 34 months demonstrated extensive involvement of the trachea and two foci of invasion were diagnosed,
including one at the pneumonectomy stump. Local photodynamic therapy was undertaken but the patient died of complications after the
procedure. Three biopsies were analysed. (b) µMCC results for chromosome 3 are shown for all three biopsies and demonstrate regional
ampliﬁcation between 178 and 185 Mb. Using the low-resolution markers there is an increase in 3q ampliﬁcation of the later lesions
(HG5 and CA2) compared to HG11, conﬁrmed on higher resolution junction analysis as shown in (c). Data from HG5 has been published
previously [14]#.( c ,d )I t e r a t i v eµMCC experiments were performed to deﬁne the centromeric and telomeric amplicon boundaries for each
biopsy, using DNA derived from peripheral blood leukocytes (PBLs) of the same individual as a control. There was a common telomeric
boundary for all three biopsies to a resolution of 1416 bps in the interval 185, 077, 260–185, 078, 676 within introns 1–2 of the gene
PARL. The centromeric boundary again lay within an L1 element for the two later lesions. HG11 did not share the centromeric boundary;
with similar copy pre- and post- the L1 repeat element, however, there was evidence of an adjacent amplicon boundary.
there was sufﬁcient DNA available from diagnostic
biopsies, taken at the same time and from the same
anatomical sites as the research biopsies HG11 and
CA2, to perform TP53 mutational analysis. In both
biopsies there was a common mutation in exon 5 of
TP53 (see Supporting information, Figure S2), again
consistent with these lesions having a clonal origin.
Case 3 (patient 026)
Patient 026 had a successful right lower lobe lobec-
tomy for SQC. At the post-operative surveillance
bronchoscopy there was high-grade dysplasia near
the lobectomy stump in the bronchus intermedius. In
addition, a ‘control’ biopsy from the main carina also
showed high-grade dysplasia. HGD of the bronchus
intermedius (HG12,13) progressed to microinvasive
cancer, whereas at the main carina (HG7) it did
not. The structure of the 3q amplicon in this patient
was different, with a clear centromeric boundary, but
in this case the amplicon extended to the telom-
ere. µMCC analysis of the centromeric amplicon
boundaries of the three biopsies was consistent with
their sharing a monoclonal origin. We have previ-
ously demonstrated progressive SOX2 ampliﬁcation
in the two bronchus intermedius samples from this
patient (HG12 and 13) [14]. The current data con-
ﬁrm progressive ampliﬁcation of the whole ampliﬁed
3q segment in the course of clinical progression. The
common centromeric amplicon boundary is retained
but the amplitude and internal structure of the 3q ampli-
con changes. It is again noteworthy that the main carina
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Figure 3. Patient 026—clinical progression is associated with
progressive and clonal changes in amplicon structure. (a,# b)
Comparison of three biopsies from patient 026, who entered the
surveillance programme after surgical resection of the right middle
andlowerlobesforSQC;twobiopsies(HG7and12)takenattheﬁrst
surveillance bronchoscopy, and another (HG13) at a subsequent
bronchoscopy at month 5. Photodynamic therapy was performed
with good effect after a diagnosis of microinvasive cancer at the
same anatomical site as HG12 and HG13 in month 13. The µMCC
data from chromosome 3 suggest an incremental increase in 3q
ampliﬁcation between HG12 and HG13, and they also suggest
that all three biopsies share a common centromeric amplicon
boundary. (c) On high-resolution analysis, this was conﬁrmed to lie
in the interval 129, 680, 327–129, 700, 853 bps, with the results
suggesting deletion of a genomic segment immediately proximal
to the amplicon.
dysplastic lesion, which did not have the more marked
3q ampliﬁcation seen in the lesions from the bronchus
intermedius, did not progress.
Discussion
We have used µMCC to closely interrogate regional
genomic events in archived microdissected bronchial
biopsies. Field cancerization in the bronchial tree is
often described, both in clinical practice and in terms of
molecular biomarkers, but the mechanism and natural
history of this process remains unclear. One question
is whether dysplastic bronchial cells can migrate and
disperse intra-epithelially to colonize the epithelial
layer prior to breaching the basement membrane. The
three patients discussed had no evidence of invasive
lung cancer (radiological or otherwise) at the point of
entry into the longitudinal study. Patient 002 did not
have invasive disease prior to enrolment and, although
the others did, all three are instructive.
The ﬁrst ﬁnding is that in patients without overt
lung cancer, a precisely resolved amplicon boundary
can be used to deﬁne a monoclonal origin of pre-
invasive bronchial biopsies that are both anatomically
separate and molecularly heterogeneous. It has been
suggested before that such boundaries, resolved at
lower resolution, can be viewed as markers of clonality
[18]. Although many cancers are characterized by
regional ampliﬁcation encompassing particular genes,
the speciﬁc structure of these events varies from
individual cancer to individual cancer. With respect
to 3q ampliﬁcation, the scale of the region involved
is often many megabases in size. There are no data
to suggest a speciﬁc ‘hot spot’ for 3q ampliﬁcation
in squamous lung cancer. The evidence from our
previous studies and those of others suggest that the
structure and boundaries of the 3q amplicon varies
tremendously between lesions from different individual
patients [14–16,24]. Therefore, amplicon boundaries
common to separate biopsies from a single individual
could be regarded as personalized markers of clonality.
Further, for patient 002, both centromeric and telomeric
boundaries are shared. These shared biomarkers in
the three patients presented indicate a clonal origin
for the separate biopsies in each individual and are
consistent with a previous case report of widespread
clonal dissemination prior to invasion [11]. The use of
amplicon boundaries to infer clonality is also supported
by the data from Patient 017, that both lesions tested
shared a common somatic mutation in TP53.T h e
involvement of repeat elements in amplicon boundaries
is consistent with what others have shown in genome-
wide studies of structural rearrangements in invasive
cancer [25].
These data, using precisely delineated amplicon
boundaries as genomic biomarkers, conﬁrm that clonal
expansion and dispersal of cells occurs and that sub-
clonal populations emerge with varying molecular
characteristics and clinical outcomes. The lesions stud-
ied, with the exception of HG11 and CA2 in case 2,
were distinct in terms of their chromosome 3 proﬁle,
consistent with the existence of intra-epithelial sub-
clonal diversity. This is interesting in the context of
recent work on Barrett’s oesophagus, in which mea-
sures of clonal diversity were robust predictors of
progression to cancer [26]. Although this is a small
cohort, the other consistent observation in the current
cases is that the amplitude of 3q ampliﬁcation pre-
dicts which lesion is likely to progress; and further, that
there is incremental 3q ampliﬁcation in those lesions
that do progress. The progression of dysplasia to inva-
sion is generally held to reﬂect ongoing selection of
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clonally advantageous genetic events. However, the
contribution of regional genomic events to neoplas-
tic progression is a focus of some debate—whether
it is of pathogenic consequence or an epiphenomenon
reﬂecting genome instability. 3q ampliﬁcation may be
selectively neutral or it may be a critical stage in the
development of squamous lung cancer. In support of
the latter, the almost uniform ﬁnding of 3q ampliﬁ-
cation in invasive squamous lung cancer [27] and its
selection in the progression to invasion points to a sig-
niﬁcant and perhaps obligate role in the pathogenesis of
SQC. Whether SOX2 is the main target of this ampliﬁ-
cation or one of a number of target oncogenes that are
co-ampliﬁed remains unclear.
This is a short case series, reﬂecting the difﬁ-
culty in recruiting to this type of longitudinal bron-
choscopic study. However, as with prior individual
case reports [5,11], but this time using an individ-
ualized genomic biomarker, this provides convincing
evidence that widespread pre-invasive clonal dispersal
is one mechanism underpinning ﬁeld cancerization in
the lung. This work demonstrates the potential value of
longitudinal studies; there is a pressing need for similar
larger-scale studies, particularly in high-risk individu-
als who do not have a history of lung cancer.
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